via Reuters
---
Tune in on Friday for some Washington headline crapola!
Most Popular
Sponsored
AXSM jumps 22.9% on Alzheimer's drug approval; analysts raise price targets to $255.
PWR beats revenue/EPS estimates, lifts guidance. Strong backlog growth signals robust demand.
Heathrow's £49B runway faces airline pushback over costs; China fund eyes exit amid risk.
ZTS's 9.1% revenue growth & 16.2x P/E show promise; IBM & CSGP face headwinds with soft growth & high P/E.
Amtrak secures $33B infrastructure funds, cutting costs on Baltimore tunnel project to $5B.
Micron's revenue booms on AI demand, but cyclical risks loom. Priced low at 8.6x earnings, will it soar or crash?
WDAY's 3x P/S valuation & slow ARR growth raise flags. ALIT's sales drop & EPS decline make it risky.
Sponsored
Must Read
